| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S17420 R73136 |
Madley-Dowd_SE (Topiramate) (Controls exposed to LTG) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: Yes Partial overlapping |
0.93 [0.55;1.57] excluded (control group) |
15/264 243/5,035 | 258 | 264 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17421 R73142 |
Madley-Dowd_SE (Topiramate) (Controls unexposed, general pop) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Partial overlapping | 0.80 [0.48;1.33] | 15/264 147,608/2,651,210 | 147,623 | 264 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17422 R73148 |
Madley-Dowd_SE (Topiramate) (Controls unexposed, sibling) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD-8/9/10 codes and/or ADHD medication prescription - Mean 5-20 years old (according groups) | during pregnancy (anytime or not specified) | population based cohort retrospective | sibling excluded | Adjustment: Yes Partial overlapping |
0.51 [0.19;1.35] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17285 R72375 |
Madley-Dowd_UK (Topiramate) (Controls exposed to LTG) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes |
0.43 [0.06;3.43] excluded (control group) |
-/154 14/939 | - | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17270 R72376 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, general pop) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 0.71 [0.10;5.32] | -/154 4,794/514,066 | - | 154 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17278 R72377 |
Madley-Dowd_UK (Topiramate) (Controls unexposed, sibling) (Mixed indications), 2024 | Attention Deficit Hyperactivity Disorder - ICD10 codes and/or ADHD medication prescription - Median follow up 5.41 (3.59-8.40) years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | sibling excluded | Adjustment: Yes |
0.25 [0.02;2.67] excluded (control group) |
-/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17468 R73416 |
Dreier (Topiramate) (Epilepsy) (Controls exposed to LTG), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
3.19 [1.85;5.50] C excluded (control group) |
16/290 95/5,288 | 111 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17469 R73426 |
Dreier (Topiramate) (Epilepsy) (Controls unexposed, sick), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 2.38 [1.40;4.06] | 16/290 528/22,203 | 544 | 290 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8589 R48828 |
Richards (Topiramate) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.18 [0.01;3.16] C excluded (control group) |
0/28 13/149 | 13 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8590 R48829 |
Richards (Topiramate) (Controls unexposed, NOS) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No | 0.42 [0.03;6.93] C | 0/28 11,841/286,966 | 11,841 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8582 R48827 |
Bromley (Topiramate), 2016 | Maladaptive behavior: Attention (BASC) (5-9 years old) | during pregnancy (anytime or not specified) | retrospective cohort (registry) | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) | 1.00 [0.43;2.31] | -/27 -/55 | - | 27 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8615 R48830 |
Rihtman (Topiramate) (Mixed indications), 2012 | Cognitive problems/inattention (Parent questionnaire) (Conners' rating scale - revised) (mean age around 4 years old) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) Matched | 4.37 [0.91;21.04] | -/8 -/18 | - | 8 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.31 [0.71;2.44] | 160,008 | 771 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Topiramate) (Controls unexposed, general pop) (Mixed indications; 2: Topiramate) (Controls unexposed, general pop) (Mixed indications; 3: Topiramate) (Epilepsy) (Controls unexposed, sick; 4: Topiramate) (Controls unexposed, NOS) (Indications NOS; 5: Topiramate; 6: Topiramate) (Mixed indications;
Asymetry test p-value = 0.9167 (by Egger's regression)
slope=0.3254 (0.5623); intercept=-0.1551 (1.3928); t=0.1113; p=0.9167
excluded 8589, 17468, 17420, 17422, 17285, 17278